MOMarta Olah

Marta Olah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marta Olah has a total of 202 co-authors. Here are the top co-authors by number of shared publications:

  • Philip Lawrence De Jager

    Center for Translational & Computational Neuroimmunology, Department of Neurology and the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York, USA

    12 shared publications
  • David A. Bennett

    Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA

    11 shared publications
  • Julie A. Schneider

    Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA

    8 shared publications
  • Andrew F. Teich

    Columbia University

    6 shared publications
  • John F. Tuddenham

    Center for Translational & Computational Neuroimmunology, Neuroimmunology Division, Department of Neurology and the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, United States

    6 shared publications
  • Mariko Taga

    Center for Translational & Computational Neuroimmunology

    6 shared publications

Latest Publications

  • Open Access

    Dense CRISPR Mapping of the WAVE Complex Identifies Pharmacological Modulators of AD-Linked Myeloid Migration

    by Jason C. Ngo, Yice Xu, Marta Olah, Falak Sher

    Although genetic risk for Alzheimer’s disease (AD) strongly converges on microglial pathways, the druggable functional protein regions that control disease-relevant microglial behaviors remain largely unknown. Here, we applied dense CRISPR-Cas9 mutagenesis and CRISPRtile-based functional mapping to the WAVE regulatory complex (WRC), a central regulator of actin remodeling and cell migration. In a pooled CCL2-directed migration assay in human THP-1 myeloid cells, perturbation of NCKAP1L , CYFIP1 , and BRK1 impaired migration and revealed divergent effects among WRC paralogs. Residue-level analysis mapped discrete migration-associated functional regions within CYFIP1 and NCKAP1L, including a CYFIP1 regulatory hotspot and a prioritized NCKAP1L region nominated for pharmacological targeting. Human single-nucleus datasets identified NCKAP1L as a microglia-enriched WRC component expressed across diverse microglial states. Machine-learning-guided compound prediction nominated Montelukast sodium and Piperacetazine, which we experimentally validated as negative and positive modulators of chemokine-directed migration, respectively. These findings establish WRC-dependent migration as a pharmacologically tunable myeloid process relevant to AD.

  • Open Access

    Identification of regulatory networks involved in microglia subset specification

    by Jason Ngo, Emily Lee, Nivedita Nimmagadda, Vilas Menon, Falak Sher, Marta Olah

    Background: We have recently established that microglia in the aged and AD human brain exist in discrete, transcriptionally defined states that have complex associations with clinicopathological features of AD (PMID: 33257666). This multifaceted relationship made it clear that we should develop approaches that allow for fine‐tuning of microglia population structure in order to achieve therapeutic benefit in AD. However, how Ad genes affect the cell intrinsic regulatory networks that shape human microglia phenotypes is yet unknown. To fill in this gap we investigated how AD genes affect the transcriptional regulatory networks that underlie microglia phenotypic specification. Method: To achieve this goal, we utilized CROP‐seq, that enables pooled CRISPR screens with single‐cell transcriptome resolution. To assemble the guide RNA (gRNA) library for this study, we focused on nascent AD drug targets that were nominated by the National Institute on Aging's AMP‐AD consortium and TREAT‐AD centers and were expressed in microglia. gRNA library transduction was performed according to our recently published protocol (PMID: 38600587), and the cells were then submitted to a modified single cell RNA‐sequencing pipeline on the 10x Genomics Chromium platform. Result: Generally, we found that genetic perturbation of AD genes in microglia resulted in changes in transcriptional regulatory networks associated with inflammation and lipid metabolism. More specifically, interestingly, the microglia subsets that were most affected by perturbations in AD genes were the previously described cluster 8 and cluster 9 microglia (PMID: 33257666). Previously we found cluster 8 microglia subset to be enriched in genes associated with metabolic changes while cluster 9 was characterized by genes involved cell proliferation. Both of these subsets had a negative association tau pathology in a large ROS/MAP transcriptomic dataset, suggesting that these microglia phenotypes might be protective in AD and that perturbations in AD genes might dysregulate the transcriptional regulatory networks involved in phenotypic specification of these subsets. Conclusion: Our findings prioritize two human microglia subsets as being primarily affected by perturbations in AD genes, and identify transcriptional regulatory networks that could be targeted to modulate microglia population structure in a way that will potentially support the maintenance and/or restoration of tissue homeostasis in AD.

  • Open Access

    Single-cell transcriptomic landscape of the neuroimmune compartment in amyotrophic lateral sclerosis brain and spinal cord

    by John F. Tuddenham, Masashi Fujita, Emily Lee, Nivedita Nimmagadda, Anthony Khairallah, Claire Harbison, Xena E. Flowers, Guillermo Coronas-Samano, Silas Maniatis, Aidan Daly, et al.

    Development of therapeutic approaches that target specific microglia responses in amyotrophic lateral sclerosis (ALS) is crucial due to the involvement of microglia in ALS progression. Our study identifies the predominant microglia subset in human ALS primary motor cortex and spinal cord as an undifferentiated phenotype with dysregulated respiratory electron transport. Moreover, we find that the interferon response microglia subset is enriched in donors with aggressive disease progression, while a previously described potentially protective microglia phenotype is depleted in ALS. Additionally, we observe an enrichment of non-microglial immune cell, mainly NK/T cells, in the ALS central nervous system, primarily in the spinal cord. These findings pave the way for the development of microglia subset-specific therapeutic interventions to slow or even stop ALS progression.


  • Open Access

    A proteogenomic tool uncovers protein markers for human microglial states

    by Philip De Jager, Verena Haage, Alex Bautista, John Tuddenham, Victoria Marshe, Rebecca Chiu, Yunduo Liu, Tsering Lama, Shane Kelly, Neelang Parghi, et al.

    Human microglial heterogeneity has been largely described using transcriptomic data. Here, we introduce a microglial proteomic data resource and a Cellular Indexing of Transcriptomes and Epitopes by Sequencing panel enhanced with antibodies targeting 17 microglial cell surface proteins (mCITE-Seq). We evaluated mCITE-Seq on HMC3 microglia-like cells, induced-pluripotent stem cell-derived microglia (iMG), and freshly isolated primary human microglia. We identified novel protein microglial markers such as CD51 and relate expression of 101 cell surface proteins to transcriptional programs. This results in the identification and validation of three protein marker combinations with which to purify microglia enriched with each of 23 transcriptional programs; for example, CD49D, HLA-DR and CD32 enrich for GPNMBhigh (“disease associated”) microglia. Further, we identify and validate proteins - SIRPA, PDPN and CD162 – that differentiate microglia from infiltrating macrophages. The mCITE-Seq panel enables the transition from RNA-based classification and facilitates the functional characterization and harmonization of model systems.

  • Open Access

    A proteogenomic tool uncovers protein markers for human microglial states

    by Verena Haage, Alex R. Bautista, John Tuddenham, Victoria Marshe, Rebecca Chiu, YunDuo Liu, Tsering Lama, Shane S. Kelly, Neelang A. Parghi, Junho Park, et al.

    Human microglial heterogeneity has been largely described using transcriptomic data. Here, we introduce a microglial proteomic data resource and a Cellular Indexing of Transcriptomes and Epitopes by Sequencing panel enhanced with antibodies targeting 17 microglial cell surface proteins (mCITE-Seq). We evaluated mCITE-Seq on HMC3 microglia-like cells, induced-pluripotent stem cell-derived microglia (iMG), and freshly isolated primary human microglia. We identified novel protein microglial markers such as CD51 and relate expression of 101 cell surface proteins to transcriptional programs. This results in the identification and validation of three protein marker combinations with which to purify microglia enriched with each of 23 transcriptional programs; for example, CD49D, HLA-DR and CD32 enrich for GPNMB high (“disease associated”) microglia. Further, we identify and validate proteins - SIRPA, PDPN and CD162 – that differentiate microglia from infiltrating macrophages. The mCITE-Seq panel enables the transition from RNA-based classification and facilitates the functional characterization and harmonization of model systems.


  • Open Access

    A factor-based analysis of individual human microglia uncovers regulators of an Alzheimer-related transcriptional signature

    by Victoria S. Marshe, John F. Tuddenham, Kevin Chen, Rebecca Chiu, Verena C. Haage, Yiyi Ma, Annie J. Lee, Neil A. Shneider, Julian P. Agin-Liebes, Roy N. Alcalay, et al.

    Human microglial heterogeneity is only beginning to be appreciated at the molecular level. Here, we present a large, single-cell atlas of expression signatures from 441,088 live microglia broadly sampled across a diverse set of brain regions and neurodegenerative and neuroinflammatory diseases obtained from 161 donors sampled at autopsy or during a neurosurgical procedure. Using single-cell hierarchical Poisson factorization (scHPF), we derived a 23-factor model for continuous gene expression signatures across microglia which capture specific biological processes (e.g., metabolism, phagocytosis, antigen presentation, inflammatory signaling, disease-associated states). Using external datasets, we evaluated the aspects of microglial phenotypes that are encapsulated in various in vitro and in vivo microglia models and identified and replicated the role of two factors in human postmortem tissue of Alzheimer’s disease (AD). Further, we derived a complex network of transcriptional regulators for all factors, including regulators of an AD-related factor enriched for the mouse disease-associated microglia 2 (DAM2) signature: ARID5B , CEBPA , MITF , and PPARG . We replicated the role of these four regulators in the AD-related factor and then designed a multiplexed MERFISH panel to assess our microglial factors using spatial transcriptomics. We find that, unlike cells with high expression of the interferon-response factor, cells with high expression of the AD DAM2-like factor are widely distributed in neocortical tissue. We thus propose a novel analytic framework that provides a taxonomic approach for microglia that is more biologically interpretable and use it to uncover new therapeutic targets for AD.


  • Open Access

    Mapping the neuroimmune landscape of Alzheimer’s disease in African Americans

    by Nkechime E. Ifediora, Nivedita Nimmagadda, Emily Lee, Peter D. Canoll, Julie A. Schneider, David A. Bennett, Vilas Menon, Lisa L. Barnes, Marta Olah

    Background: African Americans (AA) are disproportionally burdened by Alzheimer’s disease (AD), but there is a scarcity of research focusing on understanding the neuroimmune component of AD pathogenesis in this population. It is generally accepted that microglia would be an ideal therapeutic target for AD and that genetic, lifestyle, societal and environmental factors and stressors have the potential to shape microglia phenotypes and their contribution to neurodegenerative processes. The overarching goal of the current study is to establish the population structure of microglia in older AAs and to investigate the relationship of the different microglia subsets with histopathological hallmarks of brain aging and AD in AAs.Method: We utilized our established pipeline to isolate live microglia (and other immune cells) from human brain and investigate them at the single cell level using a multi‐omic approach employing transcriptomic, epigenetic and proteomic profiling. This approach, that has recently yielded the first map of microglia population structure in the aged human brain of NHW donors, has been supplemented with in situ investigation of microglia phenotypes and their association with AD pathology in archival tissue specimens.Result: We isolated and profiled live microglia from the dorsolateral prefrontal cortex and the anterior watershed deep white matter of 10 AA donors from the Minority Aging Research Study (MARS). Both of these brain regions have been previously associated with cognitive decline. Using single cell RNA‐sequencing, unsupervised hierarchical clustering of the data revealed nine distinct microglia phenotypes: two homeostatic subsets and seven differentiated subsets, similarly to what we previously described in NHW donors. Intriguingly, we detected a different population structure of microglia in AA donors when compared to NHWs. To establish an in depth understanding of these findings we investigated the chromatin accessibility and proteomic profile of the different subsets as well as their relationship to histopathological traits of brain aging in AA donors.Conclusion: While microglia in the cortex and white matter of older AA donors acquire the same functional phenotypes as microglia in the brains of NHW donors, they display a distinct population structure. Our findings underline the importance of studying the neuroimmune compartment of AD specifically in AAs.

  • Open Access

    AD genes and microglia phenotypes: does microglia phenotypic heterogeneity matter?

    by Marta Olah

    The view of microglial role in the pathogenesis of Alzheimer’s disease (AD) has been shaped by two major breakthroughs in the past decade: the discovery that many of the AD susceptibility genes are preferentially expressed in microglia, and the finding that microglia exist in a variety of previously not described functional phenotypes in the aged human central nervous system. As much as these discoveries brought paradigm shifts to the field, they also revealed major gaps in our understanding of the functional consequences of both the expression of AD susceptibility genes and microglia phenotypic heterogeneity. While there is progress being made in understanding the role of individual AD susceptibility genes in microglia function and what role the different microglia phenotypes might play in disease pathogenesis in AD, the connection between these two determining factors has not been established yet. In order to explore the relationship between the expression of AD susceptibility genes and the different microglia phenotypes that have been described in the aged and AD human brain, we explored the protein expression levels of AD relevant markers in a microglia subset specific way. Our findings highlight the importance of considering the phenotypic heterogeneity of microglia in the course of functional genomic studies and for any future disease modifying therapies targeting AD susceptibility genes in microglia.


  • Open Access

    Single-cell transcriptomic landscape of the neuroimmune compartment in amyotrophic lateral sclerosis brain and spinal cord

    by John F. Tuddenham, Masashi Fujita, Anthony Khairallah, Claire Harbison, Xena E. Flowers, Guillermo Coronas-Samano, Silas Maniatis, Aidan Daly, Julie A. Schneider, Andrew F. Teich, et al.

    Development of therapeutic approaches that target specific microglia responses in amyotrophic lateral sclerosis (ALS) is crucial due to the involvement of microglia in ALS progression. Our study identifies the predominant microglia subset in human ALS primary motor cortex and spinal cord as an undifferentiated phenotype with dysregulated respiratory electron transport. Moreover, we find that the interferon response microglia subset is enriched in donors with aggressive disease progression, while a previously described potentially protective microglia phenotype is depleted in ALS. Additionally, we observe an enrichment of non-microglial immune cell, mainly NK/T cells, in ALS central nervous system, primarily in the spinal cord. These findings pave the way for the development of microglia subset-specific therapeutic interventions to slow or even stop ALS progression.

  • A cross-disease resource of living human microglia identifies disease-enriched subsets and tool compounds recapitulating microglial states

    by John F. Tuddenham, Mariko Taga, Verena Haage, Victoria S. Marshe, Tina Roostaei, Charles White, Annie J. Lee, Masashi Fujita, Anthony Khairallah, Ya Zhang, et al.

    Human microglia play a pivotal role in neurological diseases, but we still have an incomplete understanding of microglial heterogeneity, which limits the development of targeted therapies directly modulating their state or function. Here, we use single-cell RNA sequencing to profile 215,680 live human microglia from 74 donors across diverse neurological diseases and CNS regions. We observe a central divide between oxidative and heterocyclic metabolism and identify microglial subsets associated with antigen presentation, motility and proliferation. Specific subsets are enriched in susceptibility genes for neurodegenerative diseases or the disease-associated microglial signature. We validate subtypes in situ with an RNAscope–immunofluorescence pipeline and high-dimensional MERFISH. We also leverage our dataset as a classification resource, finding that induced pluripotent stem cell model systems capture substantial in vivo heterogeneity. Finally, we identify and validate compounds that recapitulate certain subtypes in vitro, including camptothecin, which downregulates the signature of disease-enriched subtypes and upregulates a signature previously associated with Alzheimer’s disease.